cemiplimab+fianlimab

Phase 2Monoclonal antibody

UUniversity of Chicago

cemiplimab+fianlimab is one of 74 small molecule programs targeting Head and Neck Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Head and Neck CancerRecruiting

MelanomaRecruiting

Head and Neck CancerPhase 2

Recruiting

MelanomaPhase 2

Recruiting

Competition

Competitive Landscape

191 competitors in Melanoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

95 2

Opdivo

Bristol-Myers Squibb

Phase 3

112 3

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

35 4

Taxol

Teva

Phase 3

13 5

Tecentriq

Roche

Phase 3

11 6

Lenvima

Eisai

Phase 3

9 7

Libtayo

Regeneron

Phase 3

6 8

Intron a

Merck & Co.

Phase 3

4 9

Opdualag

Bristol-Myers Squibb

Phase 3

4 10

Fabhalta

Regeneron

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Melanoma

NCT06887088

Q4 2029

Phase 2Recruiting

Head and Neck Cancer

NCT07179315

Clinical

Trials by Indication[1]

Melanoma1 trial

Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

Recruiting·GGrupo Español Multidisciplinar de Melanoma·Phase 2·NCT06887088·33 enrolled

Head and Neck Cancer1 trial

A Randomized Phase II Trial of Cemiplimab With or Without Fianlimab in Patients With Detectable Minimal-residual Disease After Definitive Treatment for Human Papillomavirus Positive HPV(+) Head and Neck Cancer.

Recruiting·UUniversity of Chicago·Phase 2·NCT07179315·68 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for cemiplimab+fianlimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — cemiplimab+fianlimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for cemiplimab+fianlimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Chicago company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Chicago

cemiplimab+fianlimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q4 2029

Trials by Indication[1]

Melanoma1 trial

Head and Neck Cancer1 trial

References

Drug Info

Quick Facts

Related News